bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Up 142.0% in March

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 535,630 shares, a growth of 142.0% from the February 26th total of 221,303 shares. Currently, 12.2% of the shares of the company are short sold. Based on an average trading volume of 25,841,541 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Wednesday, January 21st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

bioAffinity Technologies Stock Up 0.3%

BIAF stock opened at $3.97 on Thursday. bioAffinity Technologies has a fifty-two week low of $0.69 and a fifty-two week high of $46.53. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.60 and a quick ratio of 2.58. The stock has a market capitalization of $17.87 million, a price-to-earnings ratio of -0.25 and a beta of 2.42. The business’s fifty day moving average price is $1.47 and its two-hundred day moving average price is $2.22.

bioAffinity Technologies (NASDAQ:BIAF) last announced its earnings results on Saturday, March 14th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.70) by $1.59. bioAffinity Technologies had a negative net margin of 241.93% and a negative return on equity of 301.67%. The company had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.55 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BIAF. Sabby Management LLC acquired a new stake in shares of bioAffinity Technologies in the third quarter valued at approximately $719,000. Geode Capital Management LLC bought a new stake in shares of bioAffinity Technologies in the fourth quarter valued at approximately $36,000. Finally, Scientech Research LLC acquired a new stake in bioAffinity Technologies during the third quarter worth approximately $49,000. Institutional investors and hedge funds own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.